Literature DB >> 32409678

N-Terminal guanidine derivatives of teicoplanin antibiotics strongly active against glycopeptide resistant Enterococcus faecium.

Zsolt Szűcs1,2, Ilona Bereczki1, Erzsébet Rőth1, Márton Milánkovits3, Eszter Ostorházi3, Gyula Batta4, Lajos Nagy5, Zsuzsanna Dombrádi6, Anikó Borbás1, Pál Herczegh7.   

Abstract

Antibiotic resistance is one of the major challenges in healthcare of our time. To meet this challenge, we designed and prepared guanidine and lipophilic guanidine derivatives of the glycopeptide antibiotic teicoplanin to armed them with activity against the most threatening nosocomial bacteria, multiresistant enterococci. From teicoplanin and its pseudoaglycone, a series of N-terminal guanidine derivatives have been prepared with free and amide C-terminal parts. Six aliphatic and aromatic lipophilic carbodiimides were prepared and used for the synthesis of lipophilic guanidine teicoplanin conjugates. All new N-terminal guanidine antibiotics showed high activity against a standard panel of Gram-positive bacteria. Four selected derivatives displayed excellent antibacterial activity against a series of nosocomial VanA Enterococcus faecium strains.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 32409678     DOI: 10.1038/s41429-020-0313-6

Source DB:  PubMed          Journal:  J Antibiot (Tokyo)        ISSN: 0021-8820            Impact factor:   2.649


  25 in total

1.  Lipophilic teicoplanin pseudoaglycon derivatives are active against vancomycin- and teicoplanin-resistant enterococci.

Authors:  Zsolt Szűcs; Ilona Bereczki; Magdolna Csávás; Erzsébet Rőth; Anikó Borbás; Gyula Batta; Eszter Ostorházi; Réka Szatmári; Pál Herczegh
Journal:  J Antibiot (Tokyo)       Date:  2017-02-01       Impact factor: 2.649

2.  Synthesis and biological evaluation of lipophilic teicoplanin pseudoaglycon derivatives containing a substituted triazole function.

Authors:  Zsolt Szűcs; Magdolna Csávás; Erzsébet Rőth; Anikó Borbás; Gyula Batta; Florent Perret; Eszter Ostorházi; Réka Szatmári; Evelien Vanderlinden; Lieve Naesens; Pál Herczegh
Journal:  J Antibiot (Tokyo)       Date:  2016-06-29       Impact factor: 2.649

3.  Comparative in vitro activity of oritavancin and other agents against vancomycin-susceptible and -resistant enterococci.

Authors:  Debora Sweeney; Audrey Stoneburner; Dean L Shinabarger; Francis F Arhin; Adam Belley; Greg Moeck; Chris M Pillar
Journal:  J Antimicrob Chemother       Date:  2016-11-17       Impact factor: 5.790

4.  Antibiotic effectiveness: balancing conservation against innovation.

Authors:  Ramanan Laxminarayan
Journal:  Science       Date:  2014-09-12       Impact factor: 47.728

5.  Longitudinal (2001-14) analysis of enterococci and VRE causing invasive infections in European and US hospitals, including a contemporary (2010-13) analysis of oritavancin in vitro potency.

Authors:  Rodrigo E Mendes; Mariana Castanheira; David J Farrell; Robert K Flamm; Helio S Sader; Ronald N Jones
Journal:  J Antimicrob Chemother       Date:  2016-09-08       Impact factor: 5.790

Review 6.  Antibiotic resistance in Enterococcus faecium clinical isolates.

Authors:  Vincent Cattoir; Jean-Christophe Giard
Journal:  Expert Rev Anti Infect Ther       Date:  2014-01-06       Impact factor: 5.091

7.  New semisynthetic teicoplanin derivatives have comparable in vitro activity to that of oritavancin against clinical isolates of VRE.

Authors:  Zsolt Szűcs; Eszter Ostorházi; Máté Kicsák; Lajos Nagy; Anikó Borbás; Pál Herczegh
Journal:  J Antibiot (Tokyo)       Date:  2019-03-15       Impact factor: 2.649

Review 8.  Twenty-five years of shared life with vancomycin-resistant enterococci: is it time to divorce?

Authors:  Vincent Cattoir; Roland Leclercq
Journal:  J Antimicrob Chemother       Date:  2012-12-02       Impact factor: 5.790

Review 9.  Emergence and management of drug-resistant enterococcal infections.

Authors:  Cesar A Arias; Barbara E Murray
Journal:  Expert Rev Anti Infect Ther       Date:  2008-10       Impact factor: 5.091

10.  Diazo transfer-click reaction route to new, lipophilic teicoplanin and ristocetin aglycon derivatives with high antibacterial and anti-influenza virus activity: an aggregation and receptor binding study.

Authors:  Gábor Pintér; Gyula Batta; Sándor Kéki; Attila Mándi; István Komáromi; Krisztina Takács-Novák; Ferenc Sztaricskai; Erzsébet Röth; Eszter Ostorházi; Ferenc Rozgonyi; Lieve Naesens; Pál Herczegh
Journal:  J Med Chem       Date:  2009-10-08       Impact factor: 7.446

View more
  3 in total

Review 1.  Recent Advances in the Development of Semisynthetic Glycopeptide Antibiotics: 2014-2022.

Authors:  Emma van Groesen; Paolo Innocenti; Nathaniel I Martin
Journal:  ACS Infect Dis       Date:  2022-07-27       Impact factor: 5.578

2.  Semisynthetic teicoplanin derivatives with dual antimicrobial activity against SARS-CoV-2 and multiresistant bacteria.

Authors:  Ilona Bereczki; Vladimir Vimberg; Eszter Lőrincz; Henrietta Papp; Lajos Nagy; Sándor Kéki; Gyula Batta; Ana Mitrović; Janko Kos; Áron Zsigmond; István Hajdú; Zsolt Lőrincz; Dávid Bajusz; László Petri; Jan Hodek; Ferenc Jakab; György M Keserű; Jan Weber; Lieve Naesens; Pál Herczegh; Anikó Borbás
Journal:  Sci Rep       Date:  2022-09-26       Impact factor: 4.996

3.  The First Dimeric Derivatives of the Glycopeptide Antibiotic Teicoplanin.

Authors:  Ilona Bereczki; Zsolt Szűcs; Gyula Batta; Tamás Milán Nagy; Eszter Ostorházi; Katalin E Kövér; Anikó Borbás; Pál Herczegh
Journal:  Pharmaceuticals (Basel)       Date:  2022-01-08
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.